Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1667958

registered interest
date	07/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cystic Fibrosis: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether it is his Department's policy that people with cystic fibrosis will have access to (a) Orkambi, (b) Symkevi and (c) Kaftrio through the NHS.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	346
answer	answer is ministerial correction date of answer 09/11/2023 answer text <p>Orkambi, Symkevi and Kaftrio are currently available as treatment options for eligible National Health Service patients with cystic fibrosis, under the terms of a commercial agreement reached between NHS England and the manufacturer. This agreement has enabled the collection of data to inform a full appraisal of these medicines by the National Institute for Health and Care Excellence (NICE), which is currently underway.</p><p>NICE published draft guidance on 3 November 2023 which does not recommend Orkambi, Symkevi and Kaftrio for the treatment of cystic fibrosis. The draft guidance is now subject to a public consultation and NICE’s committee will carefully consider all evidence as well as comments received during the consultation in developing its final guidance, which is expected to be published on 20 March 2024. Patients already receiving these treatments will have continued access following the publication of NICE’s final guidance, regardless of the outcome.</p> answering member constituency Colchester answering member printed Will Quince question first answered 09/11/2023 17:59:10 answering member 4423 label Biography information for Will Quince
tabling member	4523 label Biography information for Catherine West

1668183

registered interest
date	07/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Accident and Emergency Departments: Sotrovimab
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of hospitals with accident and emergency units have supplies of Sotrovimab.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	500
answer	answer is ministerial correction date of answer 13/11/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) recommends sotrovimab as an option for the treatment of patients with COVID-19 meeting specified clinical criteria and subject to a commercial arrangement agreed with the company. The National Health Service in England is legally required to make funding available for sotrovimab in line with NICE’s recommendations.</p><p>The Government secured stocks of sotrovimab on behalf of all nations in the United Kingdom. At current levels of use, driven by the existing access policies, there is sufficient stock held to last until the latter half of 2024. Discussions are ongoing with the manufacturer to ensure that stock is available through normal commercial channels when this Government-owned stock is consumed.</p><p>Information on the proportion of hospitals with accident and emergency units that have supplies of Sotrovimab is not held.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 501 question first answered 13/11/2023 10:39:40 answering member 4423 label Biography information for Will Quince
tabling member	4769 label Biography information for Daisy Cooper

1668185

registered interest
date	07/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sotrovimab
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the supply of anti-viral drug Sotrovimab for immunocompromised patients.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	501
answer	answer is ministerial correction date of answer 13/11/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) recommends sotrovimab as an option for the treatment of patients with COVID-19 meeting specified clinical criteria and subject to a commercial arrangement agreed with the company. The National Health Service in England is legally required to make funding available for sotrovimab in line with NICE’s recommendations.</p><p>The Government secured stocks of sotrovimab on behalf of all nations in the United Kingdom. At current levels of use, driven by the existing access policies, there is sufficient stock held to last until the latter half of 2024. Discussions are ongoing with the manufacturer to ensure that stock is available through normal commercial channels when this Government-owned stock is consumed.</p><p>Information on the proportion of hospitals with accident and emergency units that have supplies of Sotrovimab is not held.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 500 question first answered 13/11/2023 10:39:41 answering member 4423 label Biography information for Will Quince
tabling member	4769 label Biography information for Daisy Cooper